We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FTC Moves To Squash $3.1B CLS-Talecris Merger

Law360 (May 28, 2009, 12:00 AM EDT) -- The Federal Trade Commission has officially moved to block blood plasma-derived therapeutics company CSL Ltd.'s proposed $3.1 billion acquisition of rival Talecris Biotherapeutics, a deal the agency claims will reduce competition in the U.S. market for plasma-derivative protein therapies.

In an administrative complaint filed Wednesday, the FTC alleges the proposed acquisition would consolidate the market for protein therapies, increase the likelihood of collusion, tighten supply relative to demand and drive up prices.

Although the FTC said it had authorized its staff to seek a preliminary injunction...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.